Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors

Chemotherapy Induced Peripheral Neuropathy (CIPN) in Lymphoma : Longitudinal Follow up and Prognostic Factors.

Vincristine-induced peripheral neuropathy, which is commonly a sensorimotor neuropathy, remains a major complication of lymphoma patients treated with R-CHOP. The investigators propose a clinical, electrophysiological and biological follow up of patients treated by vincristine for lymphoma to determine the factors implied in VIPN occurrence.

Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).

Inclusion Criteria:

• Diagnosis of indolent or aggressive B/T NHL confirmed by biopsy and requiring chemotherapy after PCR decision including vincristine, RCHOP/CHOP protocol or CHOEP
• Accept to participate in the study
• Age > 18 year
• Able and willing to provide informed consent
• Affiliated to a social security system

Exclusion Criteria:

• Life-threatening emergency requiring chemotherapy in extreme urgency
• Neuro-meningeal damage at diagnosis
• Protected person (under guardianship or curators)
• Person under court protection
• Pregnant or breastfeeding woman
• Persons deprived of liberty by judicial or administrative decision
• Persons under forced psychiatric care
• Persons admitted to a health or social institution for purposes other than research
• Persons unable to express their consent